Download - Drug prescription in hepatic patients
![Page 1: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/1.jpg)
DRUG PRESCRIPTION IN HEPATIC PATIENTS
Prof. Maamoun Ashour
![Page 2: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/2.jpg)
DRUGS & LIVER
Hepatotoxicity Interactions Side effects
Low efficacy expensive
![Page 3: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/3.jpg)
DRUG HEPATOTOXICITY
Any drug can cause liver problems
![Page 4: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/4.jpg)
THE LIVER AND DRUG
Metabolism is the enzymatic conversion of one chemical compound into another.
Most drug metabolism occurs in the liver.
![Page 5: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/5.jpg)
THE LIVER AND DRUG
The liver is the principal organ that is capable of converting drugs into forms that can be readily eliminated from the body.
![Page 6: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/6.jpg)
HEPATOTOXICITY
More than 900 drugs have been implicated in causing liver injury and it is the most common reason for a drug to be withdrawn from the market.
![Page 7: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/7.jpg)
THE LIVER AND DRUG
The reactions range from mild and transient changes in the results of liver function tests to complete liver failure with death of the host.
Drugs may affect the liver adversely in more than one way.
The use of these drugs requires careful monitoring of their effects on the liver during the entire course of treatment
![Page 8: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/8.jpg)
DRUG INDUCED DISORDER CAN MIMIC ANY LIVER DISEASE
ACUTE DOSE-DEPENDENT LIVER DAMAGE (resembling acute viral hepatitis)
ACUTE DOSE-INDEPENDENT LIVER DAMAGE (resembling acute viral hepatitis)
Drugs that may cause cholestatic jaundice
![Page 9: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/9.jpg)
DRUG INDUCED DISORDER CAN MIMIC ANY LIVER DISEASE
Drugs that may cause acute fatty infiltration of the liver.
Drugs that may cause liver granulomas (chronic inflammatory nodules
Drugs that may cause active chronic hepatitis
Drugs that may cause liver cirrhosis or fibrosis
![Page 10: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/10.jpg)
DRUG INDUCED DISORDER CAN MIMIC ANY LIVER DISEASE
Drugs that may cause chronic cholestasis (resembling primary biliary cirrhosis)
Drugs that may cause damage to liver blood vessels.
Drugs that may cause liver tumors (benign and malignant)
![Page 11: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/11.jpg)
DRUG INDUCED LIVER PATHOLOGY
acute hepatitis - cholestatic jaundice
acute fatty infiltration of the liver. liver granulomas - active chronic
hepatitis liver cirrhosis or fibrosis chronic cholestasis - damage to liver blood vessels. liver tumors (benign and malignant)
![Page 12: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/12.jpg)
ACUTE DOSE-DEPENDENT LIVER DAMAGE
Drugs that may cause ACUTE DOSE-DEPENDENT LIVER DAMAGE
acetaminophen salicylates (doses over 2 grams daily)
![Page 13: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/13.jpg)
DRUGS THAT MAY CAUSE ACUTE DOSE-INDEPENDENT LIVER DAMAGE
indomethacin piroxicam diclofenac naproxen ibuprofen
isoniazid pyrazinamide
probenecid halothane
Para-aminosalicylic acid
Acebutololatenolol metoprolol
quinine quinidine
Phenytoinvalproic acid phenobarbital
ketoconazole sulindac
diltiazemverapamil
allopurinol cimetidineranitidine
penicillins sulfonamides
tricyclic antidepressants
carbamazepine
![Page 14: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/14.jpg)
ACUTE FATTY INFILTRATION OF THE LIVER
adrenocortical steroids phenothiazines sulfonamides antithyroid drugs phenytoin tetracyclines isoniazid salicylates valproic acid methotrexate
![Page 15: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/15.jpg)
DRUGS THAT MAY CAUSE CHOLESTATIC JAUNDICE
oxacillin sulfonamides erythromycin amoxicillin/clavulanate Cloxacillin cephalosporins nitrofurantoin azathioprine
![Page 16: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/16.jpg)
DRUGS THAT MAY CAUSE CHOLESTATIC JAUNDICE
danazol griseofulvin enalapril captopril carbimazole
![Page 17: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/17.jpg)
DRUGS THAT MAY CAUSE CHOLESTATIC JAUNDICE
haloperidol ketoconazole mercaptopurine oral contraceptives tamoxifen methyltestosterone thiabendazole nifedipine
![Page 18: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/18.jpg)
DRUGS THAT MAY CAUSE CHOLESTATIC JAUNDICE
penicillamine phenothiazines tricyclic antidepressants cyclosporine anti-inflammatory drugs verapamil carbamazepine
![Page 19: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/19.jpg)
DRUGS THAT MAY CAUSE LIVER GRANULOMAS (CHRONIC INFLAMMATORY NODULES
allopurinol gold
quinidine chlorpromazine
tolbutamide
nitrofurantoin sulfonamides penicillin
Diltiazemhydralazine
phenytoin carbamazepine
Aspirinphenylbutazone
isoniazid
![Page 20: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/20.jpg)
DRUGS THAT MAY CAUSE ACTIVE CHRONIC HEPATITIS
methyldopa isoniazid nitrofurantoin
![Page 21: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/21.jpg)
DRUGS THAT MAY CAUSE LIVER CIRRHOSIS OR FIBROSIS
methotrexate terbinafine HCI (Lamisil, Sporanox) nicotinic acid
![Page 22: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/22.jpg)
DRUGS THAT MAY CAUSE CHRONIC CHOLESTASIS (RESEMBLING PRIMARY BILIARY CIRRHOSIS)
chlorpromazine/valproic acid (combination)
imipramine thiabendazole phenothiazines phenytoin
![Page 23: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/23.jpg)
DRUGS THAT MAY CAUSE LIVER TUMORS (BENIGN AND MALIGNANT)
anabolic steroids oral contraceptives thorotrast danazol testosterone
![Page 24: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/24.jpg)
DRUGS THAT MAY CAUSE DAMAGE TO LIVER BLOOD VESSELS
adriamycin mercaptopurine vincristine azathioprine methotrexate vitamin A (excessive doses) cyclophosphamide/cyclo-sporine (combination) oral contraceptives Anabolic steroids
![Page 25: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/25.jpg)
HEPATOXICITY OF ANTITUBERCULOSIS DRUGS
Most of antituberculous drugs causes hepat-toxicity.
Combination of rifampicin and isoniazid increases hepatotoxicity.
Effect of silymarin when combined with antituberculous drugs.
![Page 26: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/26.jpg)
WHAT WE SHOULD DO
Drug history is mandatory in all hepatic patients.
Monitoring of liver functions in patients receiving hepatotoxic drugs.
Avoidance of unnecessary drugs and chemicals.
![Page 27: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/27.jpg)
DRUG INTERACTIONS
with Anticoagulants & antiplatelet
in hep. Patients with: Ischemic heart diseases Thrombotic manifestations Atrial fibrillations
![Page 28: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/28.jpg)
PRESCRIPTION OF ANTIPLATLETS
Clopedogril and aspirin are frequently prescribed in patients with ischemic heart diseases.
Many of these patients have liver diseases which may be associated with thrombocytopenia and manifestations of bleeding tendency.
What is the decision of the hepatologist and the cardiologist.
![Page 29: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/29.jpg)
ANTICOAGULANTS
Many hepatic patients may need anticoagulants for their cardiac
( AF) or thrombotic manifestations.
Bleeding is a risk in these patients.
![Page 30: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/30.jpg)
ANTICOAGULANTS
Budd – Chiari Syndrome
![Page 31: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/31.jpg)
B- BLOCKERS
B blockers is used to lower portal hypertension. In advanced cases of LCF when systemic blood pressure comes down:
B- blockers become a problem. When to give sympathomimetics
B blockers aggravate impotence in hepatic patients.
![Page 32: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/32.jpg)
DIURETICS
Are mandatory In ascitic patients Many complications may develop:
Muscle cramps Hypotension Gynecomastia
![Page 33: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/33.jpg)
EXPENSIVE DRUGS
Expensive Drugs
![Page 34: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/34.jpg)
EXPENSIVE DRUGS
Many drugs are expensive on individual and national bases:
Examples: Antivirals: Interferon, enticaver,
gancyclovir. Vasopressors: Terlipressin,
Somatostatin. Human albumin. Anti-tumors: Nexavar
![Page 35: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/35.jpg)
ALTERNATIVES TO EXPENSIVE DRUGS We should search for and evaluate
alternative cheap drugs. Examples: Human plasma as alternative to
albumin in hypoalbuminea. Norepinephrine as alternative to
glypressin HRS.
![Page 36: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/36.jpg)
NORADRENALIN VS TERLIPRESSIN IN PATIENTS WITH HEPATORENAL SYNDROME
Treatment of hepatorenal syndrome (HRS) is based on vasoconstrictors. Terlipressin is the one with the soundest evidence.
Noradrenalin has been suggested as an effective alternative.
![Page 37: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/37.jpg)
NORADRENALIN VS TERLIPRESSIN
Noradrenalin (0.1-0.7 microg/kg/min) and albumin.
Treatment is administered until HRS reversal or for a maximum of two weeks.
![Page 38: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/38.jpg)
NORADRENALIN VS TERLIPRESSIN
Reversal of HRS was observed in 7 out of 10 patients (70%) treated with noradrenalin and in 10 of 12 patients (83%) treated with terlipressin, p=ns.
Treatment led in both groups to a significant improvement in renal and circulatory function. No patient developed signs of myocardial ischemia.
![Page 39: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/39.jpg)
NORADRENALIN VS TERLIPRESSIN
Data suggest that noradrenalin is as effective and safe as terlipressin in patients with HRS.
![Page 40: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/40.jpg)
PLASMA VS ALBUMIN
Fresh frozen plasma is superior as it contains coagulation factors.
Controlled studies are required to clarify the advantages and disadvantages of both.
![Page 41: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/41.jpg)
Drug Abuse
![Page 42: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/42.jpg)
ABUSE OF DRUGS
Liver supports are widely prescribed in Egypt for many reasons:
Failure of antiviral drugs to achieve satisfactory cure.
Contribution of non- specialized and non- medical persons in treatment of liver diseases.
Influence of drug companies.
![Page 43: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/43.jpg)
DISADVANTAGES OF DRUG ABUSE
Possibility of hepatotoxicity Satisfaction of patients and
doctors Financial burden on patients and
government.
![Page 44: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/44.jpg)
SILYMARIN
RCT: Silymarin (Milk Thistle) does not affect hepatic disease in patients with hepatitis C unsuccessfully treated with interferon
Reference: JAMA. 2012; 308(3):274-282 Date published: 18/07/2012 16:50 Summary by: Sheetal Ladva Despite, limited and conflicted evidence on
silymarin, an extract of milk thistle, it is commonly used by patients to treat chronic hepatic disease.
![Page 45: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/45.jpg)
STUDY DESIGN
The Silymarin in NASH and C Hepatitis (SyNCH) study was a randomised, double-blind, placebo-controlled multicentre trial which evaluated the safety and efficacy of silymarin for treating chronic hepatitis C virus (HCV) infection among patients previously unsuccessfully treated with interferon (IFN)–based treatment.
![Page 46: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/46.jpg)
STUDY DESIGN
A total of 154 subjects with serum alanine aminotransferase (ALT) levels of 65 U/L or greater were randomised to 420-mg silymarin, 700-mg silymarin (both doses higher than normal doses used), or matching placebo administered three times per day for 24 weeks. The primary efficacy measure was serum ALT level of 45 U/L or less (normal range) or less than 65 U/L, provided this was at least a 50% reduction from baseline values.
![Page 47: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/47.jpg)
RESULTS
The following findings were reported: • Two subjects in each treatment group met the primary
outcome measure (3.8% [95% CI, 0.5% to 13.2%] for placebo, 4.0% [95% CI,
0.5% to 13.7%] for 420-mg silymarin, and 3.8% [95% CI, 0.5% to 13.2%] for 700-mg silymarin; P ≥ 0.99).
• There was no statistically significant difference in the mean
decline in serum ALT activity at the end of treatment across the three groups
(mean decline, −4.3 [95% CI, −17.3 to 8.7] U/L for placebo, −14.4 [95% CI, −41.6 to 12.7] U/L for 420-mg silymarin, −11.3 [95% CI, −27.9 to 5.4] U/L for 700-mg silymarin; p=0.75)
![Page 48: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/48.jpg)
RESULTS
There were no statistically significant differences in HCV RNA levels
(mean change, 0.07 [95% CI, −0.05 to 0.18] log10 IU/mL for placebo, −0.03 [95% CI, −0.18 to 0.12] log10 IU/mL for 420-mg silymarin, 0.04 [95% CI, −0.08 to 0.16] log10 IU/mL for 700-mg silymarin; P =0.54)
or quality-of-life measures.
![Page 49: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/49.jpg)
ADVERSE EVENTS
The adverse event profile of silymarin was comparable with that of placebo.
The most frequent adverse events were gastrointestinal symptoms, reported in 12% of participants receiving any silymarin dose compared with 5% receiving placebo.
![Page 50: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/50.jpg)
SILYMARIN DID NOT SIGNIFICANTLY REDUCE ALT
The authors concluded that higher doses of silymarin did not significantly reduce serum ALT levels more than placebo in participants with chronic HCV infection unsuccessfully treated with interferon-based therapy.
![Page 51: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/51.jpg)
SIDE EFFECTS OF DRUGS
Side effects of drugs
![Page 52: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/52.jpg)
SIDE EFFECTS OF DRUGS
Many drugs used to treat liver diseases have side effects:
Physicians should be aware of all possible side effects:
![Page 53: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/53.jpg)
SIDE-EFFECTS OF DRUGS
Diuretics Immunosuppressive Antivirals Vasopressors B- blockers
![Page 54: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/54.jpg)
ANTIVIRALS
Interferon and ribavirin have many side- effects especially on the hematological system. Depression and activation of auto immune diseases are among many other complications.
Pregnancy should be postponed until 6 months after end of tt.
![Page 55: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/55.jpg)
VASOPRESSORS
Ischemic manifestations are the most serious.
Before administration:
ECG, is mandatory. sublingual nitrates may be given.
![Page 56: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/56.jpg)
DIURETICS
Muscle cramps are common, gyncomastia is frequent but electrolyte disturbances and HRS are serious
Follow up with:
Na. K. and creatinine should be monitored.
![Page 57: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/57.jpg)
IMMUNOSUPPRESSIVE
Corticosteroids when prescribed will be used for long time.
Blood sugar and blood pressure should be controlled.
![Page 58: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/58.jpg)
GLUCOCORTICOIDS
Those receiving glucocorticoids were almost 7 times more likely to commit or attempt suicide, more than 5 times more likely to develop delirium, more than 4 times more likely to develop mania, and almost twice as likely to develop depression than those with the same underlying conditions who did not receive the medications
![Page 59: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/59.jpg)
GLUCOCORTICOIDS
Steroid-treated patients do not always know that the neuropsychiatric symptoms that they are experiencing are induced by the treatment.
They may, think that they are induced by the underlying disease.
![Page 60: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/60.jpg)
UNCOMMON DRUGS
Examples: D- pencilamine ( Artamine)
![Page 61: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/61.jpg)
PENICILLAMINE ( ARTAMINE)
Penicillamine is a chelating agent used in the treatment of Wilson's disease.
Its use relies on its binding to accumulated copper and elimination through urine.
![Page 62: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/62.jpg)
PENICILLAMINE ( ARTAMINE)
It is also used to reduce cystine excretion in cystinuria
Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis unresponsive to conventional therapy.
![Page 63: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/63.jpg)
PENICILLAMINE ( ARTAMINE)
Artamine should be taken on an empty stomach at least one hour before meals and two hours after food has been eaten.
Artamine has a high incidence of severe reactions therefore patients should be constantly monitored for any untoward reactions.
![Page 64: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/64.jpg)
NEW ISSUES
Interactions of new protease inhibitors:
![Page 65: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/65.jpg)
STATINS AND HCV PROTEASE INHIBITORS
When taken together with the affected statins, HIV and HCV protease inhibitors can boost the blood level of the statins, which in turn can lead to myopathy. One of the most serious forms of myopathy is rhabdomyolysis, which can damage the kidneys, possibly resulting in kidney failure and death.
![Page 66: Drug prescription in hepatic patients](https://reader038.vdocument.in/reader038/viewer/2022110307/556b2298d8b42adb338b4fcb/html5/thumbnails/66.jpg)
ANTIPLATELET THERAPY
Antiplatelet therapy is critical for the prevention of cardiovascular events in patients with or at risk for cardiovascular disease; however the reduction in thrombotic events comes at the price of bleeding, particularly upper gastrointestinal (GI) bleeding.
Therapies to minimize these risks include proton pump inhibitors (PPIs) but there is a lot of confusion around the impact of PPIs on the efficacy of various antiplatelet agents.